StocksMedium•4 November 2026•
1 min read
Caris Life Sciences Reports $275.4M Q3 Revenue and Raises Full-Year 2026 Guidance
Key Facts
1Caris Life Sciences reported Q3 revenue of $275.4 million, a 27% increase year-over-year.
2The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion.
3Clinical case volume reached approximately 61,500, consisting of over 358,000 total oncology tests during the quarter.
Caris Life Sciences reported revenue of $275.4 million for the third quarter of 2026, marking a 27% increase year-over-year. According to a statement released via PR Newswire, clinical case volume reached approximately 61,500, including over 358,000 total oncology tests during the period. Consequently, the company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion.
CAI closed at $32.85 on November 3, 2026, with the stock reaching a session high of $34 and a low of $32.14. This financial growth was primarily driven by strong performance in molecular profiling services and increased testing volumes within the oncology sector.